ISA Saúde raises $30M Series B to expand hospital-at-home Brazil.

ISA Saúde has closed a $30 million Series B round led by the International Finance Corporation (IFC), marking a significant capital injection for Brazil’s fast-growing hospital-at-home market. The round also included participation from development and impact investors, and management says the financing will underpin both geographic expansion and technology-driven service upgrades.

The investment, which also included funds such as IDB Lab, Dalus, and Endeavor Catalyst, is the largest of the year among Latin American healthcare startups. Founded in 2019 by brothers Fernando and David Pares, the company expanded its operations after acquiring Saúde C in 2022, now offering complex home care services.

Founded in 2019, ISA Saúde delivers hospital-level care in patients’ homes — from routine diagnostics and blood draws to rehabilitation and palliative programmes. The company currently treats around 1.5k patients daily across some 60 cities in Brazil, a footprint that executives intend to broaden into new metropolitan areas and regional networks.

Management outlined a multi-pronged use of proceeds: accelerate roll-out into additional cities, deepen commercial ties with Brazil’s major health insurers, broaden the clinical services offered, deploy AI tools to improve patient experience and clinical decision-making, and pursue targeted acquisitions to speed market consolidation. Co-founder and CEO Fernando Parés said the capital will help scale operations while bringing new digital and clinical capabilities to frontline teams.

Investors are banking on structural demand for hospital-at-home models across Latin America as payors and providers look for cost-efficient alternatives to inpatient care. Globally, hospital-at-home solutions have seen strong investor interest since the pandemic; in Brazil, an ageing population, rising chronic disease prevalence and pressure on hospital capacity are creating fertile conditions for home-based clinical pathways. For insurers, successful at-home programmes can reduce average length of stay and lower avoidable readmissions — a commercial pitch that has helped ISA deepen B2B pipelines.

Operationally, the fresh funding is expected to feed three priorities: expanding the clinical roster (for example, more complex IV therapies and post-acute rehab), investing in data and AI to personalise care plans and predict clinical deterioration, and building scale through M&A. The team named David Parés, CMO, as central to the clinical integration work that will be needed as the company grows its service menu.

From a market perspective, the raise underscores growing institutional appetite for healthtech platforms that combine clinical teams, logistics and digital triage. Comparable rounds in Latin America and Europe show investors are willing to back playbooks that can reduce system costs while preserving clinical outcomes. Challenges remain — notably workforce scaling, regulatory alignment with payors, and ensuring quality across dispersed geographies — but the capital gives ISA Saúde runway to professionalise operations and pursue consolidation.

For IFC, the investment aligns with its mandate to support private healthcare models that expand access and strengthen health system resilience. For ISA Saúde, the Series B positions the company to compete for larger insurer contracts and to accelerate a shift in Brazil towards outpatient and home-based acute care delivery.